Follow up of patients with gastrinoma has traditionally depended upon use of biochemical studies such as fasting serum gastrin levels, and imaging studies such as computed tomography and somatostatin receptor scintigraphy. A study of 72 consecutive gastrinoma patients revealed that serum chromogrannin A and gastrin are not sufficiently sensitive to replace serial imaging studies to detect changes in tumor burden [90].